Daewoong Pharmaceutical Co. LTD.

Quick facts

Marketed products

• Albis Tab
• Axid Capsule 150mg
• Baracross Tablet · Gastrointestinal / Digestive Health
  Baracross is a herbal combination tablet that works through multiple plant-derived compounds to support metabolic and digestive function.
• Clostridium Botulinum A Toxin
• Clostridium Botulinum Toxin Type A · Neurology; Aesthetics; Pain Management
  Clostridium botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
• DWJ1464 · Other
• Fexuprazan Hydrochloride · Gastroenterology
  Fexuprazan hydrochloride is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.
• Mucotra SR Tablet 150mg
• Placebo of DWJ1464
  A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials.
• Single group, open-label
  Unable to determine specific mechanism without drug name or identifier.
• Tiropramide HCl 100mg
• URSO Forte
• Ursodeoxycholic acid, thiamine, riboflavin
• Vemliver tablet

Phase 3 pipeline

• Atorvastatin 40mg, QD · Cardiovascular
  Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
• (D) DWC202206
  DWC202206 is an investigational therapeutic in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
• (D) DWC202207 · Oncology
  DWC202207 is a drug that targets the PD-1 receptor.
• DWC202011
  DWC202011 is an investigational therapeutic in Phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• DWC202304
  DWC202304 is a therapeutic agent that targets a specific molecular pathway.
• DWC202313, DWC202314 · Neurology
  DWC202313 and DWC202314 are botulinum toxin type A inhibitors.
• DWC202313, DWC202314P · Neurology
  DWC202313 and DWC202314P are botulinum toxin type A inhibitors.
• DWC202404, DWC202314 · Neurology
  DWC202404 and DWC202314 are botulinum toxin type A serotypes used for the treatment of various conditions.
• DWC202404, DWC202314P · Neurology
  DWC202404 is a botulinum toxin type A inhibitor.
• DWC202405 · Gastrointestinal
  DWC202405 is a small molecule drug that targets the mechanism of action of a specific enzyme.
• DWC202405, DWC202314 · Neurology
  DWC202405 and DWC202314 are both botulinum toxin type A serotypes.
• DWC202405, DWC202314P · Neurology
  DWC202405 is a botulinum toxin type A inhibitor.
• DWJ1177
  DWJ1177 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• DWJ1252
  DWJ1252 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• DWJ1276
  DWJ1276 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• DWJ1319 · Musculoskeletal / Endocrinology
  DWJ1319 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.
• DWJ1506
  DWJ1506 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• DWJ1507
  DWJ1507 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• DWJ1609
  DWJ1609 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• DWJ211 · Diabetes
  DWJ211 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.
• DWP14012 · Endocrinology / Diabetes
  DWP14012 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• DWP14012 A mg · Diabetes
  DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.
• DWP14012 B mg · Diabetes
  DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.
• DWP14012 X mg · Diabetes
  DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.
• DWP14012 Y mg · Endocrinology / Diabetes
  DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.
• DWP16001 · Endocrinology / Diabetes
  DWP16001 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• DWP16001 Amg
  DWP16001 is an AMG (likely referring to a specific molecular scaffold or mechanism class) in development by Daewoong Pharmaceutical, currently in Phase 3 trials.
• DWP450 · Diabetes
  DWP450 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
• DWP712 inj. · Diabetes
  DWP712 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.
• Gasmotin · Other
• Metformin 1500mg, QD · Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.
• Novosis(bongros/BMP-2) · Orthopedics / Bone regeneration
  Novosis is a recombinant human bone morphogenetic protein-2 (BMP-2) that promotes bone formation by stimulating osteoblast differentiation and new bone growth.
• (P) DWC202206 · Oncology
  DWC202206 is a drug that targets the PD-1 receptor.
• (P) DWC202207 · Oncology
  DWC202207 is a drug that targets the PD-1 receptor.
• Placebo of DWJ1252
  This is a placebo control and contains no active pharmaceutical ingredient.
• Placebo of Gasmotin · Gastroenterology
  This is a placebo formulation with no active pharmacological mechanism.

Phase 2 pipeline

• DWN12088 · Immunology
  DWN12088 is a small molecule that targets the S1P1 receptor.
• DWP708 · Diabetes
  DWP708 is a small molecule that targets the SGLT2 receptor.
• Envlo Tablet
• Envlomet SR Tablet · Pain management
  Envlomet SR Tablet is a sustained-release formulation of a selective alpha-2 adrenergic receptor agonist.
• Envolomet SR Tablet
• Rosuvastatin, Olmesartan Medoxomil

Phase 1 pipeline

• [14C]DWP14012
• Co-administration of Olmetec and Crestor
• Cresto · Other
• Cresto 20mg
• Cresto, Olmetec
• Diet A group
• Diet B group
• Diet C group
• DWB2001
• DWC20141
• DWC20141, DWC20142
• DWC20142
• DWC20151
• DWC20152
• DWC20161
• DWC20162
• DWC20163
• DWC20164
• DWC201903
• DWC202003
• DWC202004
• DWC202005, alone
• DWC202101
• DWC202201
• DWC202202
• DWC202203
• DWC202213
• DWC202215
• DWC202216
• DWC202307
• DWC202310 and DWC202311
• DWC202312
• DWC202313
• DWC202314
• DWC202501
• DWC202506
• DWC202511
• DWC202512
• DWJ1230
• DWJ1351

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Daewoong Pharmaceutical Co. LTD. portfolio CI brief
• Daewoong Pharmaceutical Co. LTD. pipeline updates RSS